Navigation Links
Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
Date:10/5/2007

long-term coadministration study planned for patients with routine high cholesterol, both expected to begin this year, Isis has selected 200 mg/week as its development dose.

About Familial Hypercholesterolemia

Familial hypercholesterolemia is a genetic condition that results in markedly elevated LDL-C levels beginning at birth and heart attacks at an early age. People with the disease have consistently high levels of LDL-C, which leads to premature atherosclerosis of the coronary arteries. Current therapies for FH are inadequate, and the most severely affected patients may need apheresis, an expensive and time-consuming procedure that removes the "bad" cholesterol from the blood. Homozygous FH is rare, affecting about one in one million people, but heterozygous FH is much more common with a prevalence of approximately one in every 500 people.

Conference Call Information

At 8:00 a.m. Eastern Time Monday, October 8, Isis will conduct a live webcast conference call to discuss ISIS 301012 results. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 888-211-7384 (U.S.) / 913-312-0380 (International). A replay will be available for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclus
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... North Central Surgical Center is proud to announce ... top-notch services. The hospital was the recipient for several ... , Hospital-wide, North Central was the recipient of the ... award for two years in a row (2013-2014). They ... nation for Patient Safety in 2014 and ranked among ...
(Date:9/17/2014)... blood test that measures DNA from a prostate cancer ... the state of a man,s disease, a new study ... could reveal when treatment for advanced prostate cancer ... researchers suggested. "Our study showed that a steroid ... often initially very effective started to activate harmful mutations ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of ... to develop the disease at lower body weights? One ... from traditional high-fiber, low-fat Asian diets to current westernized ... Asian heritage, says George King, M.D., Senior Vice President ... the senior author of the study. , A Joslin ...
(Date:9/17/2014)... London, UK (PRWEB) September 17, 2014 ... of the total medical technology market, focusing on molecular ... cancer, chronic diseases, and genetic testing. The IVD market ... billion by the end of 2017. The major drivers ... testing; need for speed, which is evidenced by the ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... explain the increased cases , FRIDAY, Nov. 6 (HealthDay News) ... people at higher risk of getting a type of thyroid ... related to cancer, but researchers suspect that the toxic compounds ... also unsure of why thyroid cancer rates are rising around ...
... a sneeze, people worry more about flu, heart attacks, accidents and ... may sound hard to believe, but just one sneeze is enough ... of dying from a heart attack at an early age, dying ... new research shows. , Of greater concern, however, was that people ...
... Nov. 6 HeartWare International, Inc. (Nasdaq: ... provider of less invasive, miniaturized circulatory support technologies revolutionizing ... it is scheduled to make presentations at two upcoming ... be made at the Third Annual Canaccord Adams Cardiovascular ...
... ... Award. , ... LA (PRWEB) November 6, 2009 -- Gilsbar, a national leader in health benefit ... was recently honored with Platinum-Level recognition for the American Heart Association Start! Fit-Friendly Companies ...
... ... and the recently released World Alzheimer Report declares that more than 35 million people ... innovator with 16 independent living and assisted living, and Alzheimer,s/memory care communities in Wisconsin ... of Alzheimer,s disease. , ...
... Tobacco-Free Kids, American Cancer Society, American Cancer Society Cancer ... American Legacy Foundation , WASHINGTON, Nov. 5 ... judge in Kentucky today rejected a motion by tobacco ... giving the U.S. Food and Drug Administration (FDA) the ...
Cached Medicine News:Health News:Thyroid Cancer Higher in Volcanic Areas 2Health News:Health Fears Are Nothing to Sneeze At 2Health News:Health Fears Are Nothing to Sneeze At 3Health News:HeartWare to Present at Upcoming Investment Conferences in November 2Health News:Gilsbar is Sole Louisiana Company to Win National Award from the American Heart Association 2Health News:Top 10 Ways to Prevent or Delay Alzheimer's 2Health News:Federal Judge Rejects Tobacco Companies' Effort to Block Key Provisions of New Tobacco Regulation Law 2
(Date:9/17/2014)...  Lightbeam Health Solutions announced today an agreement ... ACO) to deploy the Lightbeam population health platform ... while reducing costs. Photo - ... Care Organization is the ACO operating entity of ... is to be the premier integrated health care ...
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5
... 6 Reportlinker.com announces that a new ... catalogue. , Reportlinker Adds Gilead ... http://www.reportlinker.com/p0151769/Reportlinker-Adds-Gilead-Sciences-Inc-PharmaVitae-Profile.html , Introduction , This ... for Gilead in the prescription pharmaceutical sector. ...
... Oct. 6 Centocor Ortho Biotech Inc. and Schering-Plough ... European Commission has approved SIMPONI(TM) (golimumab) as a once-monthly, ... arthritis (RA), active and progressive psoriatic arthritis (PsA) and ... the European Union, SIMPONI is approved as a 50 ...
Cached Medicine Technology:Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 2Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 3Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
... Single use curved circular ... and titanium staples., ,The ... stapler is used throughout the ... of end-to-end, end-to-side and side-to-side ...
The Auto Suture™ EEA™ reusable stainless steel sizer set has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... is synthesized in the parafollicular C-cells of ... secretory granules. The major action of calcitonin ... inhibiting osteoclast activity, resulting in decreased mobilization ... is most evident in conditions associated with ...
... The pHEM-ALERT® test provides a method for ... The pHEM-ALERT test is comprised of a plastic ... color chart and a package insert. The plastic ... flat key. pHEM-ALERT is indicated for measuring vaginal ...
Medicine Products: